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The extracellular matrix (ECM) is in a continual state of
turnover with homeostasis maintained by balancing
synthesis and degradation rates. During progressive kidney
scarring an imbalance occurs leading to ECM accumulation.
Reduced matrix metalloproteinase (MMP) activity is believed
to central to this imbalance. However, most of the data
relating to MMPs and their natural inhibitors (tissue
inhibitors of matrix metalloproteinase (TIMP)) is based on
homogenate studies where in situ compartmentalization is
lost and thus changes in MMP activity may be artificial. To
address this we have developed a sensitive, high-resolution
in situ zymography technique and applied it, along with
immunohistochemistry, to the 5/6th subtotal nephrectomy
model of kidney scarring. ECM proteolytic activity in kidney
homogenates progressively declined post-SNx against both
gelatin (82%) and collagen I (78%) substrates. In situ
zymography revealed higher activity with both substrates
within the cytoplasm of normal tubular cells compared to the
SNx. In contrast, there was 96% greater activity in the SNx
glomeruli than normal. Immunohistochemistry confirmed a
predominantly intracellular tubular location of all MMPs and
TIMPs. Tubules showed reduced MMP-3 and elevated TIMP-2,
whereas MMP-1 increased significantly in the glomeruli,
especially in the mesangial matrix. TIMP-1 showed a fourfold
increase in the remnant kidney by Western blot analysis, but
could not be localized. Lowered MMP activity in
homogenates results from reduced intracellular activity in the
tubules, indicating that reduced MMP activity may not play a
direct role in the expansion of the tubular ECM in scarring.
However, elevated MMP-1 activity in the glomeruli may play
a significant role in initiating glomerular remodelling.
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The renal extracellular matrix (ECM) is in homeostatic
balance between synthesis and degradation. During progres-
sive kidney scarring, an imbalance occurs leading to elevated
ECM either by increased deposition or decreased breakdown,
although a combination of the two is more likely.1–3
Increased synthesis of many ECM proteins such as
collagens I, III, and IV, fibronectin, and laminin contribute
to this imbalance,4–6 however decreased proteolytic activity
leading to accumulation of ECM components is also an
important component of scarring.7 The matrix metallopro-
teinase system (MMP) is predominantly responsible for
degrading mature ECM. The family consists of 24 members,
with MMP’s 1, 2, 3, 8, 9, and 13 having significant renal
expression.3 MMPs 1, 8, and 13 are interstitial collagenases
degrading collagens I and III, whereas MMP-2 and -9 are
gelatinases which have collagen IV, fibronectin, and laminin
among their preferred substrates.8 MMP-3 is a stromeolysin
that favors basement membrane ECM proteins, particularly
fibronectin.9 The kidney also expresses three tissue inhibitors
of MMPs; tissue inhibitors of matrix metalloproteinase
(TIMP)-1, -2, and -3.10 TIMP-1 and -2 inhibit by blocking
the MMPs’ catalytic core, whereas TIMP-3 binds to ECM and
protects from MMP attack.11
Several studies describe changes in ECM proteolysis and
more specifically MMPs in end-stage kidney disease,2,7,12
although most of these are descriptive and based on
enzymatic, protein, or mRNA analysis of homogenates. All
mechanistic evidence for the potential consequences of
changes in the MMP system comes from in vitro studies,
most of which are performed on non-renal cell lines and do
not recreate three-dimensional architecture.13 In vitro studies
have focused on the effects of growth factors, such as
transforming growth factor-b1,14 on remodelling ECM by
altering expression of ECM proteins and/or enzymes and
inhibitors involved in ECM clearance. Some studies have
measured MMP activity and demonstrated reduced activity
in models of renal scarring such as unilateral ureteric
obstruction,15 and the 5/6 subtotal nephrectomy.16 These
studies all demonstrate changes in MMP’s and TIMP’s that
would be consistent with the fibrotic phenotype. However,
these studies are selective in the number of MMPs/TIMPs
they address, fail to determine overall changes in MMP
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activity against whole molecule substrates or have limited
information on the mechanism (transcription, latent activa-
tion, or TIMP) for this decrease in activity. Invariably, they
have not balanced changes in MMP activity against levels of
ECM. To address this, our previous work demonstrated
changes in the main renal MMP’s and TIMP’s at the protein
and mRNA level and related these to changes in scarring.17
However, like other studies this work was homogenate-based
making it both impossible to determine which compartments
(i.e., tubulointerstitial to glomerular, or intra to extracellular)
these changes occur in or whether these are true in situ
changes as a consequence of TIMPs and MMPs from separate
compartments mixing during homogenization. To address
this, here we have developed a high resolution, high
sensitivity in situ zymography procedure using whole
molecule substrates to localize MMP activity on tissue
sections and complemented this with an immunohistochemi-
cal investigation of the main renal MMP’s and TIMP’s to
determine those responsible for changes in proteolytic
activity in each compartment. We present data that shows
there is no MMP activity in the tubulointerstitium (TI)
extracellular environment despite significant intracellular
expression in the tubular epithelium. Further, in chronic
kidney disease, the glomerular and tubulointerstitial com-
partments independently regulate individual TIMP and
MMP expression to cause raised ECM proteolysis in the
glomerular, but reduced in the TI.
RESULTS
General observations
Subtotal nephrectomized (SNx) rats demonstrated a steady
increase in proteinuria and serum creatinine that paralleled a
reduction in creatinine clearance from day 30 onwards
(Table 1). This was consistent with glomerulosclerosis and
tubulointerstitial fibrosis as assessed by Masson’s Trichrome
staining (Table 1). To support this, sections were further
stained for alpha-smooth muscle actin and deposited ECM
proteins collagen III and IV. Alpha-smooth muscle actin
(myofibroblast marker) was detected within the media of the
renal arteries and arterioles in sham-operated rat kidneys.
Table 1 | Renal function and markers of progressive scarring in the SNx model
Serum creatinine (lmol/l) 24 h urinary protenuria (mg/24 h) Creatinine clearance (ml/min)
Days SNc SNx SNc SNx SNc SNx
7 6679.9 66.87149 61.9712.7 118.9734.8 0.970.2 1.270.6
15 59.7711.9 73.6714.9 54.7717.6 175.6718.4b 1.470.4 0.770.1
30 39.271.1 70.6711.1 33.874.4 227.9759.9b 3.672.0 0.870.3a
60 4370.8 240.37125b 59.679.6 252.6756.6b 3.471.3 1.170.6
90 3871.4 478.67106b 60.578.1 211.6720.0b 8.174.9 0.06þ 0.01b
120 3771.5 412.47120b 48.874.7 148.5720.7b 1.470.1 0.170.05b
Masson’s trichrome (%) Collagen IV (%) Collagen III (%)
Days SNc SNx SNc SNx SNc SNx
7 0.3570.1 6.870.7 6.870.7 7.470.3 0.170.0 1.170.0b
15 0.2270.1 6.570.6 6.570.6 7.871 0.270.1 1.270.1b
30 0.0770 6.670.3 6.670.3 9.870.7b 0.370.1 1.470.1b
60 0.570.17 6.670.9b 6.670.9 11.170.7b 0.170.0 2.970.4b
90 0.0570 6.770.9b 6.770.9 12.670.4b 0.170.0 5.270.2b
120 0.3770 6.671b 6.671 12.670.5b 0.370.1 7.170.4b
Values for Masson’s Trichrome, Collagen III and IV were obtained by point counting and represent the percentage of positive points per unit area.
All data is shown as mean values7s.e.m., n=4–6 per group.
aPo0.05.
bPo0.01.
Table 2 | Primary antibodies; source and application information
Target Antibody type Supplier Dilution Pretreatment
MMP 1 Sheep anti-human polyclonal The Binding site, Birmingham, UK (Cat No. PC166) 1:25 None
MMP 2 Murine anti human monoclonal TCS Cellworks, UK Botolph claydon (Cat No. ZIF 7102) 1:25 Antigen unmasking
MMP 3 Murine anti human monoclonal TCS Cellworks, UK Botolph claydon (Cat No. ZIF 7103) 1:25 Antigen unmasking
MMP 9 Murine anti human monoclonal TCS Cellworks, UK Botolph claydon (Cat No. ZIF 7109) 1:25 Antigen unmasking
TIMP 1 Mouse monoclonal Neomarkers Stratek Scientific, Suffolk, UK. (Cat No. MS-570-P0) 1:750 Western blot only
TIMP 2 Murine anti human monoclonal TCS Cellworks, UK. Botolph claydon (Cat No. ZIF 7342) 1:25 Antigen unmasking
TIMP 3 Murine anti human monoclonal TCS Cellworks, UK Botolph claydon (Cat No. ZIF 7343) 1:25 Antigen unmasking
a-SMA Murine anti human monoclonal Dako, Denmark (Cat No. M0851) 1:100 None
Collagen III Goat anti human polyclonal Southern Biotechnology, USA (Cat No. 1331-01) 1:10 Trypsin (Zymed, UK)
Collagen IV Rabbit anti human polyclonal EuroDiagnostica, Sweden (Cat No. 2233 PCO) 1:35 Microwave and trypsin
MMP, matrix metalloproteinase; a-SMA, alpha-smooth muscle actin; TIMP, tissue inhibitors of matrix metalloproteinase.
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Following SNx, alpha-smooth muscle actin immunostain
appeared in the interstitium from day 7, and increased
through the 120 period with glomeruli (pericapsular) and
mesangium involvement from day 90. Both collagens III and
IV were raised significantly in the interstitium and periglo-
merular at 7 days in the SNx compared to SNc and continued
to increase through progression of kidney scarring (Table 1).
Assessment of the ECM proteolytic activity in renal
homogenates
Using a DQTM-gelatin substrate (degraded by most of MMPs
especially gelatinases), homogenates from SNx kidneys
showed decreased proteolytic activity compared to controls
from day 30 post-SNx (Po0.01) and continued to decrease
over the 120 days (Figure 1a). With a DQTM-collagen I
substrate (degraded by interstitial collagenases such as MMP-1)
there was less degradation in the SNx homogenates than
controls from day 60 (Figure 1c). To confirm the extent of the
proteolytic activity owing to MMP action, a broad-spectrum
synthetic inhibitor of all MMPs (1–10 phenanthroline) was
added to the normal homogenate reaction for each of the
substrates tested above (Figure 1b, d). There was an almost
complete loss of proteolytic activity (491%) confirming the
extent of the degradation owing to MMPs.
In situ zymography
Using a gelatin substrate, in normal kidney there was little
degradation within the glomeruli, but considerable cleavage
of gelatin within the tubular epithelial cells (Figure 2a–e) that
could be abolished by addition of the MMP inhibitor 1–10
phenanthroline (Figure 2f–j). In SNx tissue at days 90 and
120 this was reversed. There was a marked loss of activity in
the tubular epithelium, which in some areas was almost
complete, but a considerable elevation in the level of gelatin
breakdown in the glomeruli (Figure 2a–e) that could be
blocked by 1–10 phenanthroline (Figure 2f–j). Of note was
that in the TI we were unable to detect any significant
breakdown of either gelatin or collagen I in the extracellular
areas including the tubular basement membrane in either
control or SNx tissue (Figure 2a–e). The changes in
proteolysis were quantified by image analysis, showing a
marked decrease in decay in the TI of 97% for gelatin (Figure
3a) and 90% for collagen I (Figure 3b), whereas glomerular
activity increased by 96 and 90% for gelatin and collagen I,
respectively (Figure 3a and b).
Immunohistochemical staining for the MMPs and their
inhibitors
MMP and TIMP immunostaining in the TI was consistent
with in situ zymography data, with both mainly expressed
intracellularly within the tubular compartment in both
normal and scarred sections (Figure 4). In SNx tissue,
MMP-3 staining was clearly lowered by some 54% compared
to normal in the TI by day 120 post-SNx (Figure 5), whereas
TIMP-2 was elevated from normal at the same point
(Figure 5). Point counting of staining for MMPs 1 and 2
failed to highlight any significant changes.
In the glomeruli, both MMPs and TIMPs were found in
the mesangium and in endothelial cells. Significant staining
could be identified in both the glomerular basement
membrane and mesangial matrix. There was significant
increase in immunoreactive glomerular MMP-1 (þ 98%)
by point counting in SNx animals compared to SNc
(Po0.01), whereas TIMP-3 was reduced by 47% from
normal at the same time point (day 120).
It was not possible to localize TIMP-1 by immunohis-
tochemistry or immunofluorescence in either the TI or
glomeruli irrespective of whether paraffin or cryostat sections
were used. However, TIMP-1 was detectable by Western
blotting, giving a sharp band at 27 kDa. Volume densitometry
indicated TIMP-1 was raised from day 7 onwards in the SNx
being nearly fourfold higher than control by day 120
(Figure 6).
DISCUSSION
In this study, we initially used whole molecule collagen 1 and
gelatin substrates in kidney homogenate assays to confirm
that a reduction in MMP activity is associated with the
progression of renal scarring and fibrosis in the 5/6th SNx
model as previously reported.17 This was extended using a
new high-resolution in situ zymography technique to
demonstrate that while tubulointerstitial remodelling is
associated with a low ECM proteolytic state, glomerular
disease is linked to large increases in MMP activity. Parallel
immunohistochemistry indicated glomerular activity
resulted from increased MMP-1 and reduced TIMP-3
expression. Further, we report that in the TI using both
in situ zymography and immunohistochemistry, there was
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Figure 1 | ECM proteolytic activity in kidney homogenates using
DQTM-gelatin and collagen I. Renal homogenates from normal (SNc)
and subtotal nephrectomized (SNx) kidneys were assayed for
proteolytic activity using the EnzCheck assay system using both
(a) DQTM-gelatin and (c) collagen I substrates. (b and d) To confirm
proteolytic activity was due to MMP action, a synthetic MMP inhibitor
(1–10 phenanthroline) was added to the reaction tube for control
tissue. Data presents mean change in fluorescence/min/mg
protein7s.e.m., (A) Po0.05, (B) Po 0.01, and (C) Po 0.001.
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an almost complete lack of extracellular MMP (including
TIMP) staining. In all ECM proteolytic assays we have used
the broad spectrum MMP inhibitor 1–10 phenanthroline to
demonstrate that over 91% of all activity measured is due to
MMPs, with all remaining activity able to be blocked by the
addition of phenylmethylsulphonyl fluoride (serine protein-
ase inhibitor) and E64 (cysteine proteinase inhibitor) to the
reaction (data not shown).
The differential MMP activity between glomerular and
tubulointerstitial compartments was unexpected in this
model and identification of the mechanism underlying this
beyond the scope of the present investigation. Precisely how
elevated glomerular MMP activity may lead to glomerulo-
sclerosis is unclear, however it could be hypothesized that
elevated ECM proteolysis causes damage to the glomerular
basement membrane and/or the mesangial matrix that may
initiate remodelling by triggering the compensatory over
production of ECM components resulting in both inap-
propriate and disorganized matrix. That said, there are
numerous reports in inflammatory driven glomerular disease
a b c d e
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Figure 2 | In situ zymography in kidney scarring. Representative photomicrographs of in situ activity (bright green) using a DQTM-gelatine
substrate in (a, c, and e) normal kidney (SNc) sections and (b and d) 120 days post-SNx. (f–j) Images of comparable SNc and SNx fields treated
with the MMP inhibitor 1,10 phenanthroline are shown on the lower row to demonstrate the level of activity resulting from MMP action,
(a, b, f, and g) are original magnification  100, (c and h) original magnification  200, and (d, e, i, and j) are original magnification  400.
700 000
600 000
500 000
400 000
300 000
200 000
100 000
20 000 45 000
40 000
35 000
30 000
25 000
20 000
15 000
10 000
5000
0
18 000
16 000
14 000
12 000
10 000
8000
6000
4000
2000
0
0
SNc SNxSNc + inhibitors SNc + inhibitors
SNc SNxSNc + inhibitors SNc + inhibitors SNc SNxSNc + inhibitors SNc + inhibitors
SNc SNxSNc + inhibitors SNc + inhibitors
Pi
xe
l
Pi
xe
l
Pi
xe
l
40 000
35 000
30 000
25 000
20 000
15 000
10 000
5000
0
Pi
xe
l
DQ gelatin
DQ collagen I
Tubulointerstitial activity
Glomerular activity
B
B C
C
B
B B
B B
a
b
Figure 3 | Measurement of the in situ proteolytic activity. Analysis of the in situ zymography using both (a) DQTM-gelatin and (b) collagen
substrate in remnant kidneys at day 120 post-SNx in both glomerular and tubulointerstitial compartments. Image analysis was undertaken
by measuring the number of pixels per field with fluorescence above a preset threshold. At least 10 sections were analyzed per kidney.
þ inhibitors denotes addition of MMP inhibitor 1,10 phenanthroline. Data represents mean pixel per section7s.e.m. (n¼ 5–6 kidneys per
group), (B) Po0.01, and (C) Po0.001.
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models such as nephrotoxic nephritis,18 Heymann nephritis,
and anti thy1.119 where this is reported. In these conditions
the increased glomerular MMP activity is linked to
inflammation20 and cell infiltration,21 in contrast to non-
inflammatory glomerular diseases such as diabetic
nephropathy,22 cyclosporine nephrotoxicity,23,24 and SNx
(hypertension) where a whole-kidney reduction in MMP
has previously thought to occur.17 However, it would be
naı¨ve to think that there is no inflammation or macrophage
infiltration into the glomerulus in the SNx model25 and thus
similar mechanisms may be involved to some extent. The
data here indicates a strong induction of MMP-1 within the
mesangium and thus it is likely that any mechanism will
involve a MMP-1 inducing growth factor or cytokine that
either has differential expression between glomerular and
tubulointerstitial compartments and/or acts against glomer-
ular cells, but not tubular epithelial cells. For example,
mesangial cells are known to upregulate MMP-1 in response
to interleukin-1b and interleukin-4, whereas tubular epithe-
lial cells do not seem to respond to these cytokines.15,26
Additionally, platelet-derived growth factor is a powerful
MMP-1 stimulator, and in the SNx model is believed to have
a predominantly glomerular expression.27 Changes reported
in the TI are far more in line with classical thinking with
upregulation of transforming growth factor-b1, tumor
necrosis factor-a, and monocyte chemoattractant protein-
128 capable of reducing MMP-3 and elevating TIMP-2 in this
compartment as reported. Of note in the SNx model is that
SNc SNcSNx SNx
MMP-1
MMP-2
MMP-3
MMP-9
TIMP-2
TIMP-3
Figure 4 | Immunohistochemical staining in the SNx for key MMP’s and TIMP’s. Representative photographs of MMP and TIMP
immunohistochemical staining in (a–f, and m–r) normal and (g–l and s–x) SNx kidney sections at 120 days post-SNx. In both (a–l)
tubulointerstitial and (m–x) glomerular compartments original magnification  400.
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transforming growth factor-b1 is predominantly upregulated
in the TI,27 allowing the classical inhibition of MMPs
synthesis with induction of TIMPs, but correspondingly the
lower glomerular induction would result in less inhibition of
MMP-1 synthesis caused by glomerular cytokines and growth
factors such as platelet-derived growth factor and inter-
leukin-1b and so on.
Given the significance of elevated glomerular MMP
activity that is surprisingly MMP-2 and -9 independent, the
lack of ratification of the glomerular changes with a more
quantitative technique such as RT-PCR or Western blotting
on isolated glomeruli is a study limitation. However the
increase in MMP-1 is sufficient to account for the increased
proteolytic activity, and as the increased glomerular proteo-
lytic activity holds against a collagen 1 substrate (which
gelatinases degrade poorly), it provides reassurance that the
immunohistochemistry is correct in its identification of
MMP-1 as the prime cause of elevated glomerular ECM
proteolytic activity.
A further limitation was the inability to visualize TIMP-1
by immunohistochemistry which has previously highlighted
as a key player in kidney scarring at the mRNA and protein
level in renal homogenates.17 Changes in TIMP-1 could have
a major influence on MMP activity and the importance of
TIMP-1 in both the glomerular29 and tubulointerstitial30
compartments has been highlighted. Here Western blots for
TIMP-1 demonstrate a biphasic response with high TIMP-1
immediately after resection, normalizing by day 30 before
increasing to the end of the study. Day 30 represents the
switch from compensatory growth to a scarring and fibrosis
in this model. This could therefore indicate that high TIMP-1
plays a role in hypertrophy/proliferation immediately post-
resection as suggested by others during acute wounding,31
but may then inhibit MMP action during fibrotic remodel-
ling of the remnant organ.32 However, the importance of
TIMP-1 was questioned by Eddy et al.33 who showed in the
experimental model of bovine serum albumin-induced
proteinuria in TIMP-1 knockout mice that genetic deficiency
of TIMP-1 does not appear to affect the severity of interstitial
fibrosis, raising the possibility of redundancy of TIMP-1
because of the high renal constitutive levels of TIMP-2 and/or
TIMP-3.33
The failure to localize either proteolytic activity, MMPs or
TIMPs to the tubulointerstitial interstitial space either in
control or disease tissue was surprising given the predomi-
nant extracellular action of these proteins as extensively
described in vitro.12 Given that in the glomerulus we were
able to detect numerous MMPs and TIMPs in both the
glomerular basement membrane and mesangial matrix a
technical reason seems unlikely. Examination of the literature
reveals several other studies that have reported predomi-
nantly intracellular staining15,33–36 in the tubular epithelium
with a similar staining pattern, with extracellular interstitial
staining reports very limited.12,37 Obviously both MMPs and
TIMPs have to be synthesized within the cell and are
exported through the classical endoplasmic reticulum, Golgi
apparatus, and secretary vessel route.38 Unfortunately the use
of immunohistochemistry rather than higher resolution
immunofluorescence makes it difficult to localize MMPs
and TIMPs to these structures which would suggest ‘storage
before requirement’. However the diffuse cytoplasmic stain,
the lack of any ‘granular or striated staining’ both here and by
others15,33–36 coupled with the absence of extracellular
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Figure 5 | Percentage change in MMP and TIMP
immunohistochemical staining following SNx. Point-count
analysis was used to quantify MMP and TIMP staining in the TI
(original magnification  200) and glomeruli (original magnification
 400). Twelve consecutive non-overlapping tubulointerstitial fields
and a minimum of 30 glomeruli were analyzed for each section. Data
are shown as mean percentage change from normal7s.e.m. for 120
days only, n¼ 4–6 per group; (A) Po0.05, (B) Po0.01.
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Figure 6 | Western blot analysis for TIMP-1 following SNx. Upper
panel shows a typical fluorograph from a Western blot of 120 day
remnant kidneys immunoprobed for TIMP-1. Lower graph shows
volume density measurements of fluorographs from each time point
represented as mean percentage7s.e.m. of control kidney values.
n¼ 4–6 per group (B) Po0.01, and (C) Po0.001.
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staining raises a possibility that TIMPs and MMPs may have
an additional role in the tubular epithelium to ECM
regulation; although one can not exclude a role in the
breakdown of immature ECM proteins before release. There
are reports suggesting TIMP-1 and -2 may have a role in the
control of apoptosis39–41 and in cell survival42 whereas MMP-
9 may act as an antiapoptotic factor.43 MMPs and TIMPs
may also influence cell proliferation and turnover.44,45
Various MMPs are implicated in intracellular signalling
although the precise mechanism for these functions remains
unclear.42 Therefore more detailed investigation of these
functions in the TI is required.
In this study, for the first time in the scarring kidney, we
have been able to precisely localize changes in MMP activity
that result from the balance of pro-MMPs, TIMPs, and active
MMPs without destroying the cellular compartmentalization
by homogenization and combined this with individual MMP
and TIMP localization to provide a clearer picture of in situ
MMP action. The study further highlights the limitations of
drawing conclusions based solely on mRNA and antigen
measurements with such a complex pro-enzyme/natural
inhibitor system is in place. Thus the contribution of elevated
TIMPs and reduced MMP levels and activity in glomerulo-
sclerosis and tubulointerstitial scarring remains unclear.
Subsequently the development of MMP induction/anti-
TIMP strategies to combat renal scarring may at best prove
ineffective and at worst accelerate glomerulosclerosis.
MATERIALS and METHODS
Male Wistar rats of 350–400 g were subjected to a one stage
subtotal (5/6th) nephrectomy (SNx) consisting of a left
nephrectomy with upper and lower poles resection of the
right kidney. Rats were housed 2–4 to a cage and maintained
at 201C and 45% humidity on a 12-h light/dark cycle. They
were allowed free access to standard rat chow (Labsure,
Cambridge, UK) and tap water. At days 7, 15, 30, 60, 90, and
120 post-SNx, experimental groups of 5–6 rats were killed
and the remnant kidney removed. At each time point, 4–6
control animals (SNc) were also killed that had been
subjected to a sham operation. Before killing, all rats had
their renal function (serum creatinine and creatinine
clearance) and proteinuria measured.
Assessment of kidney scarring and deposited ECM proteins
Kidney scarring was determined on formal calcium-fixed and
paraffin-embedded sections (4mm) that were stained using
Masson’s trichrome. Scarring was assessed by determining the
percentage of green (collagenous) staining using a standard
point counting approach.46 Sections were examined at 400
and  200 magnification for the glomeruli and the TI res-
pectively using a 120-square grid (100 point) for the glomeruli
and 25-point grid for TI. A total of 30 glomeruli and 12
consecutive non-overlapping cortical fields (area, 0.625 mm2)
were used for analysis. Masson’s trichrome was supported
using immunohistochemical staining for alpha-smooth muscle
actin (myofibroblasts), collagen III, and collagen IV.
Measurement of the overall proteolytic activity assay in a
kidney homogenate
To determine the overall ECM proteolytic activity in renal
tissue in the SNx model the Molecular Probes EnzCheck
Gelatinase/Collagenase Assay Kit (Cambridge Bioscience,
Cambridge, UK) was used. Two different fluorescein
conjugate substrates were analyzed. DQTM-gelatin (ED-
12054) was used as a substrate that could be degraded by
all MMPs, whereas DQTM-collagen I (D-12060) was used as
an interstitial MMP substrate for MMP-1, 8, and 13. During
DQTM labelling, fluorescein isothiocyanate and a quenching
agent are randomly attached throughout the molecule. The
cleavage of the substrate molecule results in the separation of
the quencher from the fluorescein isothiocyanate resulting in
an increase in fluorescence.
Analysis was performed as per the manufacturer’s
instructions using the 96-well enzyme immunoassay/radio-
immunoassay plate approach. Each well was set up with a
200 ml reaction volume containing either 25 ml DQTM-gelatin
(25 mg/ml) or 30 ml DQTM-collagen I (12.5 mg/ml), 25 ml of a
20% (w/v) kidney homogenate and made up to 200 ml/well
with 10 mM CaCl2, 50-mM Tris pH 7.4 buffer. The reaction
was allowed to proceed for 24 h in the dark at 281C. Readings
were taken every 15 min using a 96-well fluorescent plate
reader (F-max, Molecular devices Ltd, Sussex, England) with
Excitation/Emission at 495/515 nm, respectively. All values
were corrected against a collagenase standard curve (0–1 U/
ml). Specificity was verified by addition of the broad
spectrum MMP inhibitor 1–10 phenanthroline. Values were
corrected per milligram of protein.
In situ zymography
To detect the location of ECM proteolytic activity within
normal and scarred kidney sections, a modified in situ
zymography approach was employed on fresh cryostat
sections using the DQTM-labelled substrates described above.
This has the advantages that whole molecule substrates are
being employed (specificity) and that cleavage results in an
increase in fluorescence rather than a loss in staining giving a
significant increase in sensitivity. To limit the diffusion of
cleaved substrate and hence increase resolution, while at the
same time trying to reduce the loss of architecture seen when
applying warm agarose gel,47 we applied the substrates in a
7% polyacrylamide gel. To achieve this, 250 ml of a 1 mg/ml
solution of either DQTM-gelatine or DQTM-collagen I (Mole-
cular Probes) was placed into 1 ml of a 30% acrylamide
solution (37.5 acrylamide:1 bis acrylamide). To this was add
3.9 ml of activation buffer (50 mM Tris-HCL (pH 7.4),
150 mM Na Cl, 5 mM Ca Cl2, and 0.2 mM Na N3). The
acrylamide was then encouraged to polymerize by the
addition of 50 ml 10% ammonium persulfate and 4 ml
N,N,N0,N0-tetramethylethylenediamine (TEMED). A volume
of 200 ml of this solution was placed on top of a fresh cryostat
section, overlaid with a coverslip and placed at 371C until the
polyacrylamide gel set, at which point the edge of the cover
slip was immersed in activation buffer.
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Slides were placed in a humid chamber at room tem-
perature away from light and activation buffer replaced every
12 h to prevent the section from drying. The sections were
left for 72 h and then all examined under a fluorescent micro-
scope for changes in fluorescence resulting from substrate
cleavage. The synthetic MMP inhibitor 1–10 phenanthroline
(50 mM) was used to verify the contribution of MMPs by
incorporating it into the gel and activation buffer.
Immunohistochemistry
Neutral-buffered formalin (10%)-fixed and paraffin-
embedded 4 mm sections were dewaxed, hydrated, and had
endogenous peroxidase quenched using 3% hydrogen per-
oxide in methanol. Epitopes were unmasked specifically for
each antibody (Table 2) using either Antigen Unmasking
System (ID Labs, Glasgow, UK), 0.5% (w/v) Trypsin (Zymed,
San Francisco, CA, USA)48 or microwaving in citrate acid
buffer (9.99 mM, at pH 6) for 10 min.48 Sections were blocked
with 3% normal serum from the species in which the
secondary antibody was raised (diluted in phosphate-
buffered saline/0.1% bovine serum albumin) for 45 min at
room temperature. The primary antibody (or non-immune
serum) was applied at an optimized dilution (Table 2)
overnight at 41C. Binding was revealed using a biotinylated
anti-species antibody (45 min at room temperature) with the
VECASTAIN ABCs peroxidase kit and the substrate
30-amino-9-ethylcarbazole (Vector Laboratories, Peterborough,
UK). Sections were counterstained in hematoxylin (1:10) and
mounted in glycerine (Dako Patts, Cambridgeshire, UK).
Western blot analysis of TIMP 1
Fifteen micrograms of protein was separated on a 15%(w/v)
reducing polyacrylamide gel and transferred on to Hybond C
(Amersham Life Sciences, Backinghamshire, UK) using a
semi-dry blotter (Biorad Laboratories, Hertfordshire, UK).
This was blocked with 5%(w/v) dried milk for 1 h before
application of mouse monoclonal anti TIMP-1 (Neomarkers,
Stratech Scientific, Suffolk, UK) overnight at 41C. Binding
was revealed using an anti mouse horseradish peroxidase
conjugate (Dako Ltd, UK) and the ECL chemiluminescent
system (Amersham Life Sciences). Membranes were exposed
to Kodak XOMAT AR film and fluorographs quantified by
volume densitometry using a GS-690 scanning densitometer
with molecular analyst version 4 software (Biorad Labora-
tories). Determination of molecular weight was by compari-
son with Kaleidoscope molecular weight markers (Biorad
Laboratories Ltd).
Statistics
Mann–Whitney U-test was used to compare between the
means of non-parametric variables. Wilcoxon for non-
parametric-dependent variable, and Chi–Square tests for
binary variables. The correlations coefficient test (r-test) was
applied to assess the significance of the correlation between
two variables (Spearman’s for the non-parametric variables).
Analysis was performed using the statistical Package for
Social Science (SPSS) version 11.5 and Microsoft Excel 2000
software. Po0.05 was considered statistically significant.
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